vs
Side-by-side financial comparison of Gain Therapeutics, Inc. (GANX) and CytoMed Therapeutics Ltd (GDTC). Click either name above to swap in a different company.
CytoMed Therapeutics Ltd is the larger business by last-quarter revenue ($115.4K vs $105.4K, roughly 1.1× Gain Therapeutics, Inc.). CytoMed Therapeutics Ltd produced more free cash flow last quarter ($-855.4K vs $-6.1M).
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
CytoMed Therapeutics Ltd is a clinical-stage biopharmaceutical company focused on developing innovative allogeneic chimeric antigen receptor (CAR-T) cell therapies for treating hematological malignancies and solid tumors. It primarily serves global oncology patient populations and advances candidates targeting unmet medical needs in the immuno-oncology segment.
GANX vs GDTC — Head-to-Head
Income Statement — Q3 FY2024 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $105.4K | $115.4K |
| Net Profit | $-4.5M | — |
| Gross Margin | — | — |
| Operating Margin | -4230.3% | — |
| Net Margin | -4255.7% | — |
| Revenue YoY | — | — |
| Net Profit YoY | 4.9% | — |
| EPS (diluted) | $-0.17 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | — | $115.4K | ||
| Q3 24 | $105.4K | — | ||
| Q2 24 | $84.5K | — | ||
| Q1 24 | $115.3K | — |
| Q2 25 | — | — | ||
| Q3 24 | $-4.5M | — | ||
| Q2 24 | $-8.1M | — | ||
| Q1 24 | $-4.0M | — |
| Q2 25 | — | — | ||
| Q3 24 | -4230.3% | — | ||
| Q2 24 | -9680.3% | — | ||
| Q1 24 | -3796.7% | — |
| Q2 25 | — | — | ||
| Q3 24 | -4255.7% | — | ||
| Q2 24 | -9633.2% | — | ||
| Q1 24 | -3481.4% | — |
| Q2 25 | — | — | ||
| Q3 24 | $-0.17 | — | ||
| Q2 24 | $-0.42 | — | ||
| Q1 24 | $-0.22 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $12.0M | — |
| Total DebtLower is stronger | $494.4K | — |
| Stockholders' EquityBook value | $8.9M | — |
| Total Assets | $14.4M | — |
| Debt / EquityLower = less leverage | 0.06× | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | — | ||
| Q3 24 | $12.0M | — | ||
| Q2 24 | $16.9M | — | ||
| Q1 24 | $12.7M | — |
| Q2 25 | — | — | ||
| Q3 24 | $494.4K | — | ||
| Q2 24 | $486.4K | — | ||
| Q1 24 | $507.7K | — |
| Q2 25 | — | — | ||
| Q3 24 | $8.9M | — | ||
| Q2 24 | $11.8M | — | ||
| Q1 24 | $8.6M | — |
| Q2 25 | — | — | ||
| Q3 24 | $14.4M | — | ||
| Q2 24 | $19.2M | — | ||
| Q1 24 | $14.6M | — |
| Q2 25 | — | — | ||
| Q3 24 | 0.06× | — | ||
| Q2 24 | 0.04× | — | ||
| Q1 24 | 0.06× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.1M | $-855.3K |
| Free Cash FlowOCF − Capex | $-6.1M | $-855.4K |
| FCF MarginFCF / Revenue | -5764.6% | -741.5% |
| Capex IntensityCapex / Revenue | 0.0% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | $-855.3K | ||
| Q3 24 | $-6.1M | — | ||
| Q2 24 | $-5.8M | — | ||
| Q1 24 | $-3.6M | — |
| Q2 25 | — | $-855.4K | ||
| Q3 24 | $-6.1M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q2 25 | — | -741.5% | ||
| Q3 24 | -5764.6% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q2 25 | — | 0.0% | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
